Clinical trials: Significant Prostate Cancer
Prostate Cancer
Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance
A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer
- Trial name
- NCT01191099
- Testing
- Pimonidazol
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Prostate Cancer
Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer
The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of…
- Trial name
- SPROUT (NCT07180381)
- Testing
- PSA and MRI-monitoring
- Where
- 7 sites in Netherlands
- Volunteers
- 503 people
- Sponsor
- St. Antonius Hospital
Prostate Cancer
The TRANSLATE Trial
The TRANSLATE randomised controlled trial aims to evaluate local anaesthetic transperineal biopsy (LATP) versus transrectal ultrasound-guided (TRUS) prostate biopsy, in the evaluation of previously biopsy-naive men being…
- Trial name
- TRANSLATE (NCT05179694)
- Testing
- Prostate biopsy
- Where
- United Kingdom
- Volunteers
- 1,042 people
- Sponsor
- University of Oxford
Prostate Cancer
Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor
This trial aims to develop and validate the urinary multimarker sensor which can measure trace amounts of biomarkers from naturally voided urine in men referred with clinical suspicion of prostate cancer who have had no prior…
- Trial name
- NCT04825002
- Testing
- Urinary multimarker sensor
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Asan Medical Center
Clinically Significant Prostate Cancer
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
- Trial name
- NCT07492927
- Where
- 10 sites in United States, China
- Volunteers
- 1,700 people
- Sponsor
- Xijing Hospital
Neoplasm, Prostate
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Background: Currently, patients suspected of having prostate cancer undergo ultrasound-guided systematic biopsies of the prostate.
- Trial name
- PSMA-DOCS (NCT03149861)
- Testing
- PET/MR-ultrasound guided Fusion biopsy, Systemic TRUS guided biopsy
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
Prostate Neoplasm
Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection
This randomized controlled trial aims to assess the detection rate of clinically significant and clinically insignificant cancer of mpMRI-targeted biopsy compared to transperineal standard biopsy in men with clinical suspicion of…
- Trial name
- NCT03572946
- Testing
- Targeted prostate biopsy, Standard biopsy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Extended Systematic Versus Mri-Assisted pRostate Transperineal Biopsy
This is a randomized controlled trial to evaluate the detection of clinically significant prostate cancer (csPCa) by MRI-targeted approach (MRI-arm) versus 24-core transperineal (TP) systematic biopsy (TP-arm).
- Trial name
- SMART (NCT04685928)
- Testing
- MRI and MRI-guided prostate biopsy, TP-arm Systematic biopsy
- Where
- 8 sites in Hong Kong
- Volunteers
- 403 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Gadopiclenol in Contrast Enhanced MRI of the Prostate
The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant…
- Trial name
- NCT06226129
- Testing
- Gadopiclenol
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Cancer of Prostate
Investigation of Three Biomarkers for the Detection of Prostate Cancer
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies.
- Trial name
- NCT06554587
- Testing
- Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Medtechtomarket Consulting Ltd
Prostate Cancer
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).
- Trial name
- OU-SCC-PROBX (NCT05471128)
- Testing
- Standard of Care Biopsy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Oklahoma
Prostatic Neoplasm of Uncertain Behavior
Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Study Goal: The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared…
- Trial name
- Biopsy29 (NCT06579911)
- Testing
- High-frequency micro-ultrasound target biopsy, conventional Multiparametric MRT target biopsy
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
Prostatic Neoplasms, Prostate Cancer
Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer
This trial uses a ultra high-resolution ultrasound system and specialized transducer, intended for use in prostate imaging. The system's image resolution is significantly better than the standard of care, due to its higher…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02079025
- Testing
- High-resolution ultrasound guided prostate biopsy, Standard ultrasound guided prostate biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,676 people
- Sponsor
- Exact Imaging
Prostate Cancer
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.
- Trial name
- NCT03081481
- Testing
- PRX302
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Sophiris Bio Corp
Significant Prostate Cancer
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer.
- Trial name
- NCT03237702
- Testing
- Multi-Carotenoids
- Where
- Taiwan
- Volunteers
- 2,000 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)
This is a single centre prospective observational noninterventional study of men with histological confirmed prostate cancer, high risk disease and not positive for metastatic disease planned to receive Radiotherapy and 18 months…
- Trial name
- PROCITT (NCT01418040)
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- Calvary Mater Newcastle, Australia
Prostate Cancer Diagnosis
PSMA PET Scan and mpMRI for Prostate Cancer Detection
Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate cancer as compared to mpMRI alone.
- Trial name
- NCT05820724
- Testing
- PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Prostate Cancer, Magnetic Resonance Imaging
Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa).
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy
- Trial name
- NCT03044197
- Testing
- MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Prostate Cancer
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis
Prostate biopsy usually combines magnetic resonance imaging/ultrasound (MRI/US) cognitive fusion targeted biopsy with systematic biopsy.
- Trial name
- IBIS-PC (NCT07795723)
- Testing
- MRI/US Cognitive Fusion Targeted Biopsy Plus Ipsilateral Systematic Biopsy, MRI/US Cognitive Fusion Targeted Biopsy Plus Bilateral Systematic Biopsy
- Where
- China
- Volunteers
- 454 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer (Diagnosis), Prostate Cancer
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
Prostate cancer diagnosis based on systematic or MRI-targeted biopsy is associated with substantial overdiagnosis and unnecessary invasive procedures.
- Trial name
- INSIGHT-PCa (NCT07398690)
- Testing
- Diagnostic Procedure
- Where
- South Korea
- Volunteers
- 1,432 people
- Sponsor
- In Gab Jeong, MD